| 130.59 -2.74 (-2.06%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 158.52  |
1-year : | 185.15 |
| Resists | First : | 135.72 |
Second : | 158.52 |
| Pivot price | 123.67 |
|||
| Supports | First : | 114.25 |
Second : | 100.98 |
| MAs | MA(5) : | 130.02 |
MA(20) : | 119.78 |
| MA(100) : | 126.6 |
MA(250) : | 134.69 |
|
| MACD | MACD : | 3.6 |
Signal : | 2 |
| %K %D | K(14,3) : | 85.9 |
D(3) : | 88.5 |
| RSI | RSI(14): 61.3 |
|||
| 52-week | High : | 175.77 | Low : | 100.98 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RGEN ] has closed below upper band by 20.4%. Bollinger Bands are 1.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 135.83 - 136.52 | 136.52 - 136.96 |
| Low: | 128.88 - 129.77 | 129.77 - 130.35 |
| Close: | 129.31 - 130.66 | 130.66 - 131.52 |
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Thu, 11 Jun 2026
RBC Capital Resumes Repligen Corp (RGEN) Stock Coverage. Here’s Its View - Insider Monkey
Tue, 09 Jun 2026
Repligen Corp (RGEN) Shares Surge 3.8% -- What GF Score of 83 Te - GuruFocus
Mon, 08 Jun 2026
Repligen Corporation (RGEN) Stock Analysis: Unlocking a 43.98% Upside in Bioprocessing Innovation - DirectorsTalk Interviews
Thu, 04 Jun 2026
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Thu, 04 Jun 2026
Repligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow - Seeking Alpha
Mon, 01 Jun 2026
Repligen Corporation (RGEN) Stock Analysis: Unpacking a 44% Potential Upside for Investors - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 56 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 5.2 (%) |
| Held by Institutions | 119.6 (%) |
| Shares Short | 5,700 (K) |
| Shares Short P.Month | 5,490 (K) |
| EPS | 0.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 37.33 |
| Profit Margin | 6.7 % |
| Operating Margin | 8.8 % |
| Return on Assets (ttm) | 1.1 % |
| Return on Equity (ttm) | 2.5 % |
| Qtrly Rev. Growth | 14.8 % |
| Gross Profit (p.s.) | 7.19 |
| Sales Per Share | 13.53 |
| EBITDA (p.s.) | 2.37 |
| Qtrly Earnings Growth | 47.9 % |
| Operating Cash Flow | 131 (M) |
| Levered Free Cash Flow | 69 (M) |
| PE Ratio | 145.1 |
| PEG Ratio | 1.9 |
| Price to Book value | 3.49 |
| Price to Sales | 9.65 |
| Price to Cash Flow | 56.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|